- Products & Services
- Knowledge Base
PHOENIX, AZ, November 19, 2018 /24-7PressRelease/ -- Kalos Therapeutics, Inc. is a biomedical company developing a class of therapeutic peptides to fight cancer. These peptides have already shown significant clinical activity in cardiovascular, cancer and veterinary indications. Kalos' drugs replicate a natural, anti-proliferative activity by disrupting tubulin activity.
Our lead drug candidate, KTH-222, is a safe, non-toxic drug which may be used as 1) a front-line therapy, 2) a long-term maintenance therapy or 3) a co-therapy which reduces time to chemo resistance and minimizes chemo side-effects. KTH-222 reduces tumor size while addressing complications, such as metastasis, thereby, allowing the patient to maintain a quality of life not seen with chemo therapy treatments alone.
Initial cancer markets include: pancreatic, ovarian, prostate, lung and liver. An animal division will develop drugs for the treatment of cancer and renal disease, congestive heart failure and epistaxis.
The OCMX™ is pleased to announce the listing of Kalos Therapeutics Inc to its online portal which offers Investors and Advisors the ability to participate in this opportunity.
The OCMX™ has spent considerable time completing its due diligence on Kalos Therapeutics Inc and concluded that there is indeed a tremendous opportunity for Investors and Advisors.
The OCMX™ noted that Kalos Therapeutics Inc exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.
George Colberg, Co-Founder, CEO, Chairman
Mr. Colberg is a seasoned corporate finance and management executive. He was CEO of Primary Inc., a company where he pioneered the plan for acquisitions and the business model initiating early efforts in personalized medicine, electronic medical record meshed with patient data and billing and the advanced use of diagnostics. Prior to Primary Care he was a Vice President at the Financial Group managing syndications and equity investment research while raising in excess of $100 million.
Mr. Colberg developed the corporate philosophy of Kalos, identified and shaped the strategy behind the primary products, and the commercialization plan for Kalos. He raised the seed round, series A and B rounds and grant financing totaling $3.5 million. He recruited the executive team and scientific advisory board and oversees the clinical development plan. Mr. Colberg set the strategy for securing US and EU IP patents and the Orphan Drug Designation.
Mr. Colberg completed his Bachelor of Science from San Diego State University and attended University California, Berkeley for a Certification as a Biomedical Executive.
Jay Merritt, MD, President and Chief Medical Officer
Dr. Merritt is a medical oncologist with over 20 years' experience as a biotechnology executive. He most recently served as President and Chief Medical Officer at Adventrx Pharmaceuticals. He was founding CEO of Imagine Pharmaceuticals, a venture stage company with a small molecule approach to facilitate drug uptake across the blood brain barrier.
He began his industrial career at the Upjohn Company leading early stage oncology and infectious diseases clinical research and he played a key role in launching Upjohn's HIV research program. He subsequently held senior management positions at IDEC Pharmaceuticals (now Biogen Idec), Viagene Inc. and Introgen Therapeutics, successfully advancing ground-breaking biological modalities such as therapeutic monoclonal antibodies for cancer and rheumatologic diseases, and retroviral and adenoviral gene transfer technologies for cancer and HIV.
Dr. Merritt graduated from Johns Hopkins University and received an M.D. from the University of Vermont. He trained in Internal Medicine and Medical Oncology at the University of Wisconsin where he was also appointed Assistant Scientist in the Biophysics Laboratory.
Michael Kozlowski, PhD, Chief Science Officer
Dr. Michael Kozlowski is an Associate Professor at the Arizona College of Optometry (AZCOPT) at Midwestern University and CSO at Kalos therapeutics. Prior to Kalos, Dr. Kozlowski spent over 25 years in drug discovery and development for several clinical applications including cancer, age-related macular degeneration, and CNS disorders, and has over 40 peer-reviewed publications and over a dozen issued US patents.
He has worked with large pharmaceutical (Pfizer, BMS) and biotechnology companies (Geron, Telik, Axiom, Kreido Laboratories). Dr. Kozlowski has held positions ranging from Research Scientist to Chief Scientific Officer. Dr. Kozlowski holds a BS in Biology from Caltech, a PhD in Neuroscience from the University of California at Irvine, and an OD from the New England College of Optometry.
SCIENTIFIC ADVISORY BOARD
Daniel D. Von Hoff, MD, FACP
Chief of the Scientific Advisors Board, NCI; Dream Team Leader, Stand up 2 Cancer, Former President, AACR CSO- US Oncology; Director, Arizona Cancer Center; Professor of Medicine, University of Arizona Health Sciences Center
Marc B. Garnick, MD
Special Governmental Advisor to FDA;
Professor of Medicine at Harvard Medical School;
Editor in Chief, HMS Annual Report on Prostate Diseases;
Former Trustee of Penn Medicine the Perelman School of Medicine
Patrice P. Rioux, MD, PhD
Chief Medical Officer, Raptor Pharmaceuticals; Medical Director Biogen Europe; VP of Medical Research, Repligen
ABOUT THE OCMX™
The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Email: [email protected]
# # #